Übersicht – Neue Therapieoptionen beim metastasierten nicht-kleinzelligen Lungenkarzinom

• Literatur

• 1 Reck M, Popat S, Reinmuth N et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2014; 25 Suppl 3: iii27-39
• 2 Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin vs. solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30: 2055-2062
• 3 Yang J, Sequist L, Schuler M et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014; 32 abstr. 8004
• 4 Park K, Tan EH, Zhang L et al. afatinib vs. gefitinib as first-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations. Lux-Lung 7. In ESMO ASIA. Singapore 2015
• 5 Sequist LV, Soria JC, Goldman JW et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372: 1700-1709
• 6 Janne PA, Yang JC, Kim DW et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-1699
• 7 Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel vs. placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665-673
• 8 Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib vs. docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-155
• 9 Herbst RS, Baas P, Kim DW et al. Pembrolizumab vs. docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015; pii: S0140-6736(15)01281-7 [Epub ahead of print]
• 10 Brahmer J, Reckamp KL, Baas P et al. Nivolumab vs. Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 123-135
• 11 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab vs. Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 1627-1639
• 12 Temel JS, Greer JA et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742